Comparison · NCT01774344-deaths
Regorafenib (Stivarga, BAY73-4506) vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Regorafenib (Stivarga, BAY73-4506) vs Placebo: deaths from any cause. Trial comparisons, record NCT01774344-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01774344-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.866 | 0.828 | 0.897 | wilson | |
| Risk in group 2 | 0.912 | 0.863 | 0.944 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0456 | -0.0957 | 0.0118 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.95 | 0.895 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | 0.626 | 0.35 | 1.12 | log | |
| Number needed to treat, for one fewer death from any cause on Regorafenib (Stivarga, BAY73-4506) than on Placebo | 21.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Regorafenib (Stivarga, BAY73-4506) | Description: Subjects received regorafenib 160 mg (4 \*40 mg tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC. | 324 | 374 | EG001 |
| Group 2 | Placebo | Description: Subjects received placebo matched to regorafenib tablets orally every day for 3 weeks followed by 1 week off treatment plus best supportive care(BSC). | 176 | 193 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse event data were collected after start of study drug administration until 30 days after end of study treatment over a period of approximately three years
Source ClinicalTrials.gov
Trial
- Title
- Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
- NCT number
- NCT01774344
- Phases
- PHASE3
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Regorafenib (Stivarga, BAY73-4506), Placebo
- Lead sponsor
- Bayer
- Results first posted
- 2017-06-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01774344?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01774344-deaths